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Abstract 
Background: SHINBARO is a refined herbal formulation used to treat inflamed lesions and bone diseases. This study 
aimed to investigate the anti‑osteoarthritic activities of intra‑articular administration of SHINBARO and determine its 
underlying molecular mechanism in a monosodium iodoacetate (MIA)‑induced osteoarthritis rat model.
Methods: Male Sprague–Dawley rats received a single intra‑articular injection of MIA into the infrapatellar ligament 
of the right knee. Subsequently, the rats were treated with normal saline, SHINBARO, and diclofenac once daily for 
21 days. Rats treated with normal saline, but not MIA, comprised the control group. Histological changes in the femur 
of the MIA‑induced osteoarthritis rat model were observed by micro‑computed tomography scanning and staining 
with hematoxylin and eosin, and safranin‑O fast green. Serum levels of PGE2 and anti‑type II collagen antibodies in the 
MIA‑induced osteoarthritis rat model were measured using commercial kits. Protein levels of inflammatory enzymes 
(iNOS, COX‑2), pro‑inflammatory cytokines (TNF‑α, IL‑1β), and inflammatory mediators (NF‑κB, IκB) in cartilaginous 
tissues were determined by western blot analysis.
Results: Intra‑articular administration of SHINBARO (IAS) at 20 mg/kg remarkably restrained the decrease in bone 
volume/total volume, being 28 % (P = 0.0001) higher than that in the vehicle‑treated MIA group. IAS (2, 10, and 
20 mg/kg) treatment significantly recovered the mean number of objects values with increased percentage changes 
of 13.5 % (P = 0.147), 27.5 % (P = 0.028), and 44.5 % (P = 0.031), respectively, compared with the vehicle‑treated MIA 
group. The serum level of PGE2 in the IAS group at 20 mg/kg was markedly inhibited by 60.6 % (P = 0.0007) compared 
with the vehicle‑treated MIA group, and the anti‑collagen type II antibody level in the IAS group was reduced in a 
dose‑dependent manner. IAS (20 mg/kg) effectively suppressed the induction of inflammation‑mediated enzymes 
(iNOS and COX‑2) and pro‑inflammatory cytokines (TNF‑α and IL‑1β). IAS treatment also downregulated the NF‑κB 
level and increased the IκB‑α level in the MIA‑ induced osteoarthritis rat model.
Conclusion: SHINBARO inhibited PGE2 and anti‑type II collagen antibody production and modulated the balance of 
inflammatory enzymes, mediators, and cytokines in the MIA‑induced osteoarthritis rat model.
Keywords: SHINBARO pharmacopuncture, Monosodium iodoacetate‑induced osteoarthritis, Intra‑articular 
administration
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Background
Osteoarthritis (OA) is a degenerative joint disease char-
acterized by abrasion of articular cartilage and trabecular 
bone loss [1]. The chance of developing the disease 
increases with age, knee joint lesions, obesity, infectious 
diseases, and various joint inflammations [2–5]. Several 
previous studies suggested that abrasion of articular car-
tilage, subchondral bone sclerosis, and excessive forma-
tion of trabecular bone might cause OA [6–8]. Other 
studies highlighted the importance of prostaglandins in 
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OA treatment [9]. Prostaglandins are enhanced by stim-
uli, such as lipopolysaccharide, sodium nitroprusside, 
or physical injury associated with OA [10], increased 
macrophage migration into the synovial fluid, activated 
nuclear factor (NF)-κB as an inflammatory transcription 
factor, and both cyclooxygenase (COX)-2 and inducible 
nitric oxide synthase (iNOS) as inflammatory enzymes 
[11, 12].
Regarding alleviation of OA, although non-steroidal 
anti-inflammatory drugs including acetaminophen are 
mainly prescribed during the early stage of OA, these 
drugs do not effectively prevent the progression of 
OA [13] and there have been some problems with side 
effects involving the gastrointestinal tract and kidneys. 
In particular, the use of COX-2 inhibitors is restrictively 
allowed because of significant side effects on cardiovas-
cular function [14].
Monosodium iodoacetate (MIA) is an inhibitor of glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) that 
results in a reduction of glycolysis and causes articular 
cartilage changes related to the histological and mor-
phological features of OA by impeding integration of 
the chondral structure and inducing cell death of chon-
drocytes [15]. Furthermore, MIA causes a repeated pro-
gression of synovial hyperplasia and inflammatory cell 
infiltration, destroys articular cartilage, and induces bone 
loss and chondral deformation [16]. Injection of MIA 
into the knee joints of rats is considered a suitable model 
that resembles the phenomena observed in human OA 
and is thus applied for evaluation of chondroprotective 
activity [17].
SHINBARO is a purified herbal formulation con-
taining six traditional medicines, Ledebouriellae Radix 
(Fang Feng), Achyranthis Radix (Huai Niu Xi), Acantho-
panacis Cortex (Wu Jia Pi), Cibotii Rhizoma (Gou Ji), 
Glycine Semen (Hei Dou), and Eucommiae Cortex (Du 
Zhong), that has been used to treat inflamed lesions and 
bone diseases [18]. Pharmacopuncture is a new form of 
therapy that involves both herbal medicine administra-
tion and acupuncture to manage blood extravasation 
and improve blood flow. Therefore, pharmacopunc-
turology is considered to be a medical practice in ori-
ental medicine that involves administration of refined 
herbal extracts into acupoints [19]. The anti-inflamma-
tory activity of oral SHINBARO treatment was dem-
onstrated in an adjuvant-induced OA rat model [18]. 
However, the anti-arthritic activity of SHINBARO phar-
macopuncture and its underlying mechanism have not 
yet been determined.
This study aimed to investigate the anti-osteoarthritic 
activities of intra-articular administration of SHINBARO 
and determine its underlying molecular mechanism in an 
MIA-induced OA rat model.
Methods
Preparation and composition of SHINBARO
SHINBARO was prepared by Hanpoong Pharmaceutical 
Co. Ltd. (Jeonju, Republic of Korea). The mixture of six 
crude drugs, Ledebouriellae Radix (4.444 g), Achyranthis 
Radix (4.444 g), Acanthopanacis Cortex (4.444 g), Cibotii 
Rhizoma (2.778 g), Glycine Semen (2.778 g), and Eucom-
miae Cortex (1.389 g), was powdered and boiled for 3 h 
in distilled water (1 L). The mixture was then subjected to 
ultrafiltration through Whatman grade 2 qualitative filter 
paper (GE Healthcare Life Sciences, Marlborough, MA, 
USA) to exclude components with molecular weights 
above 10,000. The resulting filtrate was lyophilized to a 
powder using a rotary evaporator (Eyela, Miyagi, Japan), 
and stored at 4  °C until use. SHINBARO was adminis-
tered intra-articularly at a dose of 2, 10, or 20  mg/kg in 
saline and orally at a dose of 20 or 200  mg/kg in saline. 
The same volume of saline was used as a vehicle in con-
trol rats. The validation of SHINBARO was performed 
by high-performance liquid chromatography (Waters™ 
600 s controller, 626 pump, temperature control module, 
in-line degasser, 717 plus autosampler, and 996 photodi-
ode array detector; Waters, Bedford, MA, USA) analysis 
of each ingredient extract using the following six indica-
tor biological components [18]: cimifugin for Ledebouri-
ellae Radix; 20-hydroxyecdysone (0.311–0.312  mg/g) for 
Achyranthis Radix; acanthoside D (0.577–0.578 mg/g) for 
Acanthopanacis Cortex; onitin-4-O-β-D-glucopyranoside 
for Cibotii Rhizoma; genistin (0.0426–0.0427  mg/g) for 
Glycine Semen; and geniposide (0.431–0.432  mg/g) for 
Eucommiae Cortex. SHINBARO was further standard-
ized for quality control according to the regulations 
imposed by the Korea Food and Drug Administration.
Animals
Male Sprague–Dawley rats (200–220  g) were obtained 
from Central Laboratory Animal Inc. (Seoul, Korea), and 
housed in solid-bottom cages with free access to food 
and water. The temperature was maintained to 22 ± 2 °C, 
and a 12-h/12-h light/dark schedule was implemented. 
Prior to use, the animals were allowed 1 week for accli-
matization within the work area environment. All animal 
experiments were approved by the local Animal Eth-
ics Committee of Seoul National University (Additional 
file  1), and carried out in accordance with the Institu-
tional Animal Care and Use Committee Guidelines of 
Seoul National University (Permission Number: SNU-
120904-7) and the ARRIVE guideline (Additional files 2 
and 3).
MIA‑induced OA rat model
Rats were anesthetized with diethyl ether and given 
a single intra-articular injection of 2.5  mg MIA 
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(Sigma–Aldrich, St. Louis, MO, USA) into the infrapatel-
lar ligament of the right knee [20]. MIA was dissolved in 
0.9 % normal saline and administered in a 25-µL volume. 
The rats were arbitrarily divided into eight groups con-
taining six rats each. Subsequently, the rats were treated 
with normal saline (vehicle-treated MIA group), 2, 10, or 
20  mg/kg of SHINBARO by intra-articular administra-
tion (intra-articular SHINBARO group; IAS group), 20 
or 200 mg/kg of SHINBARO by oral administration (oral 
SHINBARO group; OS group), and 5 mg/kg of diclofenac 
by oral administration (diclofenac group) once daily for 
21  days. Rats treated with normal saline, and not MIA, 
were used as a control group (Table 1). The SHINBARO 
concentrations and MIA injection volume were selected 
based on previous evaluations [21]. After 21  days of 
treatment, the animals were euthanized and blood sam-
ples were collected for serum isolation. The femurs were 
dissected and stripped of soft tissue for analysis of the 
trabecular microarchitecture.
Morphological analysis of bone loss
The bone microarchitecture of the femur in the region at 
0.6–2.1 mm from the growth plate was scanned using a 
micro-computed tomography (micro-CT) system (Sky-
Scan 1076; SkyScan, Aartselaar, Belgium). The X-ray 
source was set at a voltage of 50  kV and a current of 
200 µA and filtered with a 0.5-mm aluminum filter. The 
scanning angular rotation was 180° with an angular step 
of 0.5°. The voxel size was fixed at 8.9 µm. The morpho-
metric indices of the bone region were determined from 
the micro-CT data on 3D images using CTan software 
(SkyScan 1076; SkyScan, Aartselaar, Belgium). The fol-
lowing measures characterizing the three-dimensional 
structure of the trabecular bone were determined: bone 
volume of interest (BV; µm3); bone volume fraction (bone 
volume/total volume (BV/TV); %); and mean number 
of objects per slice (Obj.N). BV indicates the total vol-
ume of extracted cartilage from the same parts in each 
group. The ratio of BV/TV is the segmented trabecular 
bone volume to total tissue volume. Obj.N implies the 
connectivity of the specimens, which consisted of several 
cross-sectional slices of cartilage in a three-dimensional 
structure.
Histopathological analysis
The right knee joints from the tibia to the distal meta-
tarsal including the tarsal joint were resected and fixed 
with 10 % neutral-buffered formalin for 24 h at 4 °C. The 
fixed specimens were decalcified with 20 % formic acid 
for 3 days and embedded in paraffin. Sections of the tis-
sue specimens were acquired from the paraffin blocks 
at 5  µm thickness, deparaffinized, and rehydrated in 
the order of xylene, absolute alcohol, and 50 % alcohol. 
The rehydrated sections were stained with hematoxy-
lin and eosin (H&E) for observation of morphologi-
cal changes in the articular tissues and safranin-O fast 
green (SOFG) for evaluation of the proteoglycan (PG) 
contents.
Measurement of prostaglandin E2 (PGE2) level
The serum PGE2 levels were measured by enzyme immu-
noassay (EIA) using a prostaglandin E metabolite EIA 
kit (Cayman Chemical Company, Ann Arbor, MI, USA). 
Briefly, aliquots of prepared standard solutions and sam-
ple sera were plated in 96-well plates from the PGE2 EIA 
kit, and a PGE2-acetylcholinesterase (AChE) conjugate 
(PGE Tracer) and PGE2 monoclonal antibody solution 
were added and allowed to react at 4  °C for 24 h. Next, 
Ellman’s reagent, which contains an AChE substrate for 
color formation, was added to the wells and the opti-
cal density was measured at 412  nm (VersaMax ELISA 
Microplate Reader; Molecular Devices, Sunnyvale, CA, 
USA). The PGE2 concentrations in the serum samples 
were determined using a four-parameter logistic equa-
tion (logit(B/B0)  =  ln[B/B0/(1–B/B0)]) by comparisons 
with the absorbances of the PGE2 standard solutions at 
several concentrations (8, 16, 31, 62, 125, 250, 500, and 
1000 pg/mL).
Table 1 Effect of SHINBARO on change in body weight of MIA-induced OA rat model
SHINBARO or diclofenac was treated daily for 21 days after 2 weeks of OA induction by intra-articular injection of MIA. Body weight was measured once every 7 days 





Vehicle Intra‑articular SHINBARO (mg/kg) Oral SHINBARO (mg/kg) Diclofenac 
(5 mg/kg)
2 10 20 20 200
0th 305.5 ± 7.9 308.1 ± 20.4 301.2 ± 17.1 305.5 ± 11.8 306.2 ± 11.8 306.2 ± 14.5 306.0 ± 16.2 288.0 ± 13.9
7th 352.9 ± 11.6 347.6 ± 14.2 335.0 ± 14.5 352.2 ± 15.0 347.2 ± 10.7 347.3 ± 11.7 351.2 ± 12.7 317.8 ± 32.0
14th 384.5 ± 9.5 378.6 ± 17.1 365.2 ± 16.1 387.8 ± 14.1 379.3 ± 11.5 376.2 ± 11.4 387.0 ± 11.7 356.0 ± 15.5
21st 411.5 ± 15.2 402.0 ± 16.3 385.5 ± 19.7 411.5 ± 15.5 401.3 ± 12.0 395.8 ± 17.3 407.8 ± 13.1 388.5 ± 9.05
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Measurement of anti‑type II collagen antibody level
The serum anti-type II collagen antibody levels were 
assayed using a rat anti-type I and type II collagen IgG 
ELISA kit (Chondrex Inc., Redmond, WA, USA) in 
accordance with the manufacturer’s instructions.
Ex vivo biochemical analysis of inflamed tissues
The right knee joint cartilages of the rats were removed at 
the end of the treatment period. The tissues were homog-
enized using Nuclear Extract Kit (Active Motif, Carlsbad, 
CA, USA) in accordance with the manufacturer’s instruc-
tions. The protein levels of inflammatory enzymes (iNOS, 
COX-2), pro-inflammatory cytokines (tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β), and inflammatory 
mediators (NF-κB, nuclear factor of κ light polypeptide 
gene enhancer in B-cells inhibitor (IκB)) in the cartilagi-
nous tissues were determined by western blot analysis.
Western blot analysis
The proteins in the rat articular cartilage samples were 
resolved by 6–15 % sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred 
onto PVDF membranes (Millipore, Bedford, MA, USA). 
The membranes were blocked with blocking buffer, 
comprising 5  % bovine serum albumin in phosphate-
buffered saline containing 0.1  % Tween-20 (PBST), for 
1 h at room temperature. After three washes with PBST, 
the membranes were incubated with primary antibod-
ies against β-actin (1:1000), iNOS (1:1000), COX-2 
(1:1000), IL-1β (1:1000), NF-κB (1:500), IκB-α (1:200) 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
TNF-α (1:1000) (Cell Signaling, Danvers, MA, USA) 
diluted in 2.5 % bovine serum albumin overnight at 4 °C. 
The membranes were washed three times with PBST 
and incubated with corresponding secondary antibodies 
diluted in PBST (1:1000) for 2  h at room temperature. 
After three washes with PBST, the membranes were 
visualized with a WEST-ZOL plus Western Blot Detec-
tion System (Intron Biotechnology, Sungnam, Korea), 
and analyzed using an LAS 4000 system (Fuji Film Corp., 
Tokyo, Japan).
Statistical analysis
All experiments were repeated at least three times. Data 
were presented as means ±  standard derivation for the 
indicated numbers of independently performed experi-
ments. Statistical significance was assessed by one-way 
analysis of variance coupled with a Dunnett’s t test. Val-
ues of P  <  0.05 were considered statistically significant. 
All statistical analyses were performed using Graph Pad 




Changes in body weight were monitored during admin-
istration of SHINBARO or diclofenac and measured on 
days 0, 7, 14, and 21 as evaluation parameters for the 
courses of stress and toxicity in the animals. The body 
weight in the vehicle-treated MIA group increased at 
a similar rate to that in the control group (Table  1). In 
addition, the IAS group, OS group, and diclofenac group 
did not show any significant differences compared with 
the vehicle-treated MIA groups. No overt toxicity was 
observed in the IAS and OS groups compared with the 
vehicle-treated control groups.
Morphological analysis of bone loss
The destruction of the trabecular bone in the femur 
was observed by three-dimensional micro-CT to deter-
mine the effects of SHINBARO on the trabecular bone 
microarchitecture. As shown in Fig.  1, MIA caused sig-
nificant deterioration of the trabecular bone architec-
ture compared with the control group. However, IAS 
or OS treatment delayed or recovered the destruction 
of the trabecular bone in the MIA-induced OA model. 
Protective activity was also observed for oral treatment 
of diclofenac, a positive control, under the same experi-
mental conditions. In addition, the bone microstruc-
tural index parameters were measured using NRrecon 
software (Fig.  2). The BV of the trabecular bone in the 
femur was clearly decreased in the vehicle-treated MIA 
group by 22.4  % (P  =  0.0042) compared with the con-
trol group. However, IAS (20 mg/kg) treatment remark-
ably restrained the decrease in BV (P  =  0.0045), being 
40 % higher than that in the vehicle-treated MIA group. 
The BV of the trabecular bone in the femur was allevi-
ated by IAS in a dose-dependent manner and recovered 
to almost the same level as the control group. Diclofenac 
treatment insignificantly increased the BV of the trabecu-
lar bone in the femur by 13.8 % in the MIA-induced OA 
model (P  =  0.053). In addition, BV/TV was decreased 
in the vehicle-treated MIA group (22.9  %, P  =  0.0089) 
compared with the control group. IAS (2, 10, and 20 mg/
kg) treatment effectively recovered the BV/TV values 
in a dose-dependent manner with increased percent-
ages of 9.2 % (P = 0.015), 19.2 % (P = 0.001), and 28.1 % 
(P  =  0.0001), respectively, compared with the vehi-
cle-treated MIA group, while diclofenac exhibited an 
increase of 7.7 % in BV/TV. Obj.N was markedly reduced 
in the vehicle-treated MIA group (30.4  %, P  =  0.0063) 
compared with the control group, and IAS (2, 10, and 
20  mg/kg) treatment significantly recovered the Obj.N 
values with increased percentage changes of 13.5  % 
(P = 0.147), 27.5 % (P = 0.028), and 44.5 % (P = 0.031), 
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respectively, compared with the vehicle-treated MIA 
group. The diclofenac group also exhibited recovery of 
Obj.N with an increased percentage change of 18.0  % 
(P  =  0.095) compared with the vehicle-treated MIA 
group. OS (20 or 200  mg/kg) treatment also improved 
the damage to the cartilage with increased percentage 
changes of 7.7  % (P  =  0.405) and 35.3  % (P  =  0.013), 
respectively, but the activity was relatively low compared 
with that of IAS treatment.
Histopathological analysis
We performed H&E staining for the articular cartilage 
surfaces of the femoral condyle and tibial plateau to 
determine whether IAS treatment restored the damaged 
surface of the knee joint toward healing. The vehicle-
treated MIA group revealed severe irregular abrasions 
with rough edges around the femur and tibia, indicative 
of bone lysis, swelling, and tendency for patellar displace-
ment (Fig.  3). This damage was significantly attenuated 
with the appearance of smoother articular cartilage sur-
faces by IAS (20  mg/kg) treatment. MIA-induced artic-
ular cartilage damage was also restored in the positive 
control group treated with diclofenac. SOFG staining, 
which stains PGs and is indicative of the degree of degen-
eration of cartilaginous tissue [22], was performed to 
observe the changes in morphology of the cartilaginous 
tissues. The SOFG-stained control group exhibited nor-
mal cartilage PG staining, while the vehicle-treated MIA 
group revealed severely damaged cartilage with marked 
fibrillation and PG depletion. Treatment with SHIN-
BARO or diclofenac significantly suppressed the MIA-
induced loss of PG and prevented cartilage damage 
(Fig. 3).
Analysis of biomarkers in serum
The effects of IAS treatment on inflammatory biomark-
ers were determined using serum prepared from blood 
samples collected in the MIA-induced OA rat model. The 
serum PGE2 level in the MIA-treated group was signifi-
cantly increased by 67.8 % (P =  0.0045) compared with 
the control group (Fig.  4a). IAS (20  mg/kg) treatment 
markedly inhibited the elevated serum PGE2 level by 
60.6  % (P  =  0.0007) compared with the vehicle-treated 
MIA group. The serum PGE2 level in the diclofenac group 
was inhibited by 59.5  % (P  =  0.0012) under the same 
experimental conditions. Furthermore, the serum level of 
Fig. 1 Roentgenograph analysis of the knee joint after treatment of SHINBARO in MIA‑induced OA rat model. Micro‑cartilage and patellae of the 
normal and experimental animals were scanned with microCT (Skyscan1076). Data represent as the mean ± SD (n = 6). IAS intra‑articular SHIN‑
BARO, OS oral SHINBARO
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anti-type II collagen antibodies, which are responsible for 
activation of oxidative stress with the formation of perox-
ynitrite (ONOO−) [7], was increased in the MIA-treated 
group, while IAS treatment significantly decreased the 
anti-type II collagen antibody level in a dose-dependent 
manner (Fig. 4b).
Analysis of biomarkers in cartilaginous tissue
The effects of IAS treatment on the protein expres-
sion levels of inflammation-mediated enzymes, such as 
iNOS and COX-2, were determined in the MIA-induced 
OA rat model to determine the mechanism of action of 
IAS treatment on the inhibition of inflammatory bio-
marker production. Overproduction of NO and PGE2 is 
concomitant with overexpression of iNOS and COX-2, 
leading to swelling, irritation, and pain [23]. MIA treat-
ment induced overexpression of iNOS and COX-2 in 
the cartilaginous tissues, while IAS (20  mg/kg) or OS 
(200 mg/kg) treatment effectively suppressed the induc-
tion of iNOS and COX-2 expression (Fig. 5).
iNOS and COX-2 expression are regulated by NF-κB 
[24]. NF-κB is composed of p65/p50 subunits and 
exists in the cytosol as inactive heterodimers bound to 
the inhibitory protein IκB-α. IκB-α stimulated by pro-
inflammatory signals is phosphorylated by IκB kinase 
and degraded by a 26S proteasome-mediated pathway 
to facilitate translocation of NF-κB into the nucleus and 



























































































Fig. 2 Effect of SHINBARO on the bone morphometric parameters in MIA‑induced OA rat model. The bone morphometric parameters including BV 
(a), BV/TV (b), and Obj.N (c) were analyzed with micro‑CT SkyScan CTAN software. Data represent the mean ± SD (n = 6). *P < 0.05 and **P < 0.01 
indicate statistically significant differences from the vehicle‑treated MIA group. ##P < 0.01 indicates statistically significant differences from the 
control group. C control group, V vehicle‑treated MIA group, IAS intra‑articular SHINBARO group, OS oral SHINBARO group, P positive control group 
(Diclofenac 5 mg/kg)
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treatment upregulated the nuclear protein levels of the 
NF-κB subunits (p65 and p50), while IAS treatment sup-
pressed these biomarker expression levels, especially 
that of the p50 subunit (Fig. 6). In addition, the protein 
expression of IκB-α was downregulated in the vehicle-
treated MIA group compared with the control group, 
while IAS treatment increased the IκB-α level in the 
MIA-induced OA rat model. IAS treatment might inhibit 
the inflammatory responses through suppression of 
MIA-induced NF-κB activation.
Further studies were conducted to correlate the anti-
inflammatory effects of IAS treatment with the regulation 
of expression of pro-inflammatory cytokines. The effects 
of IAS treatment on the expression levels of these pro-
inflammatory cytokines were investigated in the MIA-
induced OA rat model. The protein levels of TNF-α and 
IL-1β revealed overexpression in the MIA-treated group 
compared with the control group, while IAS treatment 
suppressed the elevated expression levels of TNF-α and 
IL-1β in the cartilaginous tissues of the MIA-induced OA 
rat model (Fig. 6). Therefore, IAS treatment inhibited the 
inflammatory response through blockade of the expres-
sion of pro-inflammatory cytokines, such as TNF-α and 
IL-1β.
Fig. 3 Histopathological analysis of the knee joint tissues after treatment of SHINBARO in MIA‑induced OA rat model. The knee joint tissues from 
MIA‑induced OA rat model which was treated with vehicle, SHINBARO or diclofenac were stained with hematoxylin and eosin (H&E) and Safranin 
O‑fast green (SOFG) (magnification ×100)
Fig. 4 Effect of SHINBARO on the serum levels of prostaglandin E2 and collage‑II antibody in MIA‑induced OA rat model. Data represent the 
mean ± SD (n = 6). *P < 0.05 and **P < 0.01 indicate statistically significant differences from the vehicle‑treated MIA group. ##P < 0.01 indicates 
statistically significant differences from the control group. C control group, V vehicle‑treated MIA group, IAS intra‑articular SHINBARO group, OS oral 
SHINBARO group, P positive control group (Diclofenac 5 mg/kg)
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Discussion
OA is a degenerative knee joint disease that causes 
intense pain and functional disability [26]. The disease 
is classified into two categories: primary or idiopathic 
arthritis that involves endocrinologic, genetic, and nutri-
tional factors and secondary or subsequent arthritis that 
is incurred by injury, disorder, and malformation capable 
of causing damage to the articular cartilage [27, 28].
Although anti-inflammatory effects of OS treat-
ment were previously reported [29], the pharmacologi-
cal effects of IAS treatment, which is already practiced 
in clinical settings, and its underlying mechanisms of 
action remain to be determined. Therefore, the present 
study was conducted to investigate the anti-inflammatory 
activity of IAS treatment and its underlying mechanisms 
of action in the MIA-induced OA rat model.
The MIA used in the present study inhibits articular 
cartilage structural incorporation through suppression of 
GAPDH activity in the cartilage, leading to histopatho-
logical and pathomorphologic changes in the articular 
cartilage [30]. SHINBARO prevented the degeneration of 
the trabecular bone microarchitecture in the distal femur 
of the rat. IAS treatment also markedly restored bone 
loss in the MIA-induced OA model (Fig.  1). These data 
were supported by the protective effect of IAS treatment 
on the bone morphometric parameters (Fig. 2). In addi-
tion, no significant body changes or obvious toxicity were 
found in the IAS group (Table 1). These results indicated 
that IAS treatment not only preserves the bone mass, 
but also recovers the bone microstructural deterioration 
associated with MIA-induced OA without toxicity.
Healthy cartilage tends to maintain a balance between 
synthesis and degradation of extracellular matrix (ECM) 
components, such as PGs and type II collagen. However, 
the decomposition of the ECM becomes increased in 
inflamed cartilage, leading to an off-balance of matrix pro-
duction and damage to the cartilaginous tissues [31]. The 
H&E and SOFG staining in the vehicle-treated MIA group 
revealed significant PG loss and lesion development, and 
confirmed that the cartilage injury was attenuated by IAS 
treatment (Fig.  3). In addition, IAS treatment markedly 
reduced the elevated serum level of anti-type II collagen 
antibodies associated with MIA in a dose-dependent man-
ner (Fig.  4b). These findings indicate that IAS treatment 
might delay bone loss through decreased bone turnover.
Major biomarkers for inflammation responses were 
determined in serum to further confirm the effects of IAS 
treatment on the regulation of inflammatory responses. 
PGE2 acts as an important inflammatory mediator and 
is a major product of COX activity, which functions 
Fig. 6 Effect of SHINBARO on the protein levels of NF‑κB, IκB‑α, TNF‑α 
and IL‑1β in cartilage from the knee joint after treatment of SHIN‑
BARO in MIA‑induced OA rat model. The expressions of NF‑κB, IκB‑α, 
TNF‑α and IL‑1β in the extracted cartilage tissues were determined 
by Western blot analysis as described in the “Methods” section. Data 
were representative of three separate experiments. β‑actin was used 
as an internal standard. C control group, V vehicle‑treated MIA group, 
IAS intra‑articular SHINBARO group, OS oral SHINBARO group, P posi‑
tive control group (Diclofenac 5 mg/kg)
Fig. 5 Effect of SHINBARO on the protein levels of iNOS and COX‑2 
in cartilage from the knee joint after treatment of SHINBARO in MIA‑
induced OA rat model. The expressions of iNOS and COX‑2 in the 
extracted cartilage tissues were determined by western blot analysis 
as described in the “Methods” section. Data were representative of 
three separate experiments. β‑actin was used as an internal standard. 
C control group, V vehicle‑treated MIA group, IAS intra‑articular 
SHINBARO group, OS oral SHINBARO group, P positive control group 
(Diclofenac 5 mg/kg)
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pathologically in inflammatory, autoimmune, and neo-
plastic diseases [32]. In this study, the serum PGE2 level 
was significantly higher in the vehicle-treated MIA group 
compared with the control group, while IAS treatment 
inhibited the elevation of PGE2 production in the MIA-
induced OA rat model (Fig. 4a).
Overproduction of PGE2 is highly associated with 
overexpression of iNOS and COX-2 in inflammatory 
responses [33]. The effects of IAS on iNOS and COX-2 
protein expression levels were determined to investigate 
the mechanism responsible for the inhibition of PGE2 
production mediated by IAS treatment. IAS suppressed 
the MIA-induced overexpression of iNOS and COX-2 
protein levels in a dose-dependent manner (Fig. 5).
We further examined whether IAS treatment regulates 
the protein expression levels of upstream mediators lead-
ing to the production of iNOS and COX-2. NF-κB exists 
in the cytosol of cells as an inactive heterodimer bound to 
the inhibitory protein IκB with Rel A (p65), c-Rel, RelB, 
NF-κB1 (p50/150), and NF-κB2 (p52/100) [34]. How-
ever, NF-κB becomes degraded with IκB sequestration 
when inflammatory cytokines, TNFs, and lymphotoxins 
are activated by stimuli, such as mitogens, bacteria, ultra-
violet light, oxidants, tetradecanoyl phorbol-13-acetate, 
ionizing radiation, and phosphatase inhibitors [35–37]. 
The activated heterodimers of NF-κB subunits p65 and 
p50 in the cytosol translocate into the nucleus and bind 
to NF-κB-binding sites in gene promoters or enhancers, 
thereby inducing the transcription of downstream target 
genes, such as cytokines, cytokine receptors, cell adhe-
sion molecules, and growth factors. IκB is negatively 
regulated by phosphorylation on serine residues, which 
is controlled by two IκB kinases, IKKα and IKKβ [38]. In 
the present study, IAS treatment downregulated the pro-
tein level of NF-κB and upregulated the protein level of 
IκB (Fig. 6). These findings suggest that the anti-inflam-
matory effects of IAS treatment are associated with inhi-
bition of NF-κB activation.
The anti-inflammatory effects of IAS treatment were 
also observed by measurements of the protein expression 
levels of pro-inflammatory cytokines, such as TNF-α and 
IL-1β. These cytokines promote the catabolic processes 
in OA, causing cartilage degradation. MIA can drive the 
overexpression of pro-inflammatory cytokines, but the 
TNF-α and IL-1β levels were effectively reduced by IAS 
treatment in the MIA-induced OA model (Fig. 6). These 
data suggest that IAS treatment inhibits inflammatory 
responses by suppressing the expression of pro-inflam-
matory cytokines, including TNF-α and IL-1β.
Conclusion
SHINBARO inhibited PGE2 and anti-type II collagen 
antibody production and modulated the balance of 
inflammatory enzymes, mediators, and cytokines in the 
MIA-induced OA rat model.
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